Merck KGaA pitches in an extra $3M to support Opexa's PhIIb for MS

After gaining an option on Opexa's experimental drug for secondary progressive multiple sclerosis for only $5 million, Merck KGaA's Serono division has come up with an extra $3 million to support the biotech's ongoing Phase IIb study. The two companies struck the option deal back in 2013 on Tcelna (imilecleucel-T). It remains one of Merck KGaA's last investments in a scaled-down program for MS as the company also backs away from early-stage R&D in the field. Release

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.